OVID - Ovid Therapeutics to Host Investor Event - R&D Day on Monday October 2 2023 | Benzinga
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that it will host a Research & Development (R&D) Day investor event on Monday, October 2, 2023. The event will take place at the Company's headquarters in New York's Hudson Yards from 12:00 pm - 2:30 pm and will be webcast simultaneously.
Ovid management will provide updates on Ovid's scientific strategy and anticipated clinical development plans. Additionally, the Company's research and development leadership will review new data characterizing how the unique mechanisms of action in its pipeline address the underlying causes of neuronal hyperexcitability and may hold broader therapeutic potential in other central nervous system disorders. Also presenting will be recognized clinicians and academic thought leaders in epilepsy and rare neurological disorders, including:
- Imad Najm, M.D. – Vice Chair for Strategy and Development at the Cleveland Clinic Neurological Institute; Director of the Cleveland Clinic Epilepsy Center
- Connie Lee, Psy.D. – Chief Executive Officer and founding President of the Alliance to Cure Cavernous Malformation
- Stephen Moss, Ph.D. – Director of the Moss Labs for Neuropharmacology within Tufts University Neuroscience Department
In-person attendance is by invitation only. Those who would like to attend should contact Argot Partners on behalf of Ovid. Lunch will be served prior to the event for those attending in-person.
A live webcast of the presentation can be accessed through the Events and Presentations section ...